<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2404245204
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CELLCEPT 500 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MYCOPHENOLATE MOFETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        251.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Milano S.r.l" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Milano S.r.l
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>The full name of your medicine is CellCept 500&nbsp;mg film-coated tablets.&nbsp;</strong></p><p dir="ltr"><strong>&bull; In this leaflet the shorter name CellCept is used.</strong></p><p dir="ltr"><strong>CellCept contains mycophenolate mofetil.&nbsp;</strong></p><p dir="ltr"><strong>&bull; This belongs to a group of medicines called &ldquo;immunosuppressants&rdquo;.&nbsp;</strong></p><p dir="ltr"><strong>CellCept is used to prevent your body rejecting a transplanted organ.</strong></p><p dir="ltr"><strong>&bull; A kidney, heart or liver.&nbsp;</strong></p><p dir="ltr"><strong>CellCept should be used together with other medicines:</strong></p><p dir="ltr"><strong>&bull; Ciclosporin and corticosteroids.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>WARNING</strong></p><p dir="ltr"><strong>Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you do not fully understand these instructions, please ask your doctor to explain them again before you take mycophenolate. See also further information in this section under &ldquo;Warnings and precautions&rdquo; and &ldquo;Pregnancy and breast-feeding&rdquo;.</strong></p><p><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>Do not take CellCept:</strong></p><p dir="ltr"><strong>&bull; If you are allergic (hypersensitive) to mycophenolate mofetil, mycophenolic acid or any of the other ingredients in this medicine (listed in section 6)</strong></p><p dir="ltr"><strong>&bull; If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage.</strong></p><p dir="ltr"><strong>&bull; If you are pregnant or planning to become pregnant or think you may be pregnant</strong></p><p dir="ltr"><strong>&bull; If you are not using effective contraception (see Pregnancy, contraception and breast-feeding).</strong></p><p dir="ltr"><strong>&bull; If you are breast-feeding.</strong></p><p dir="ltr"><strong>Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr"><strong>Talk to your doctor straight away before starting treatment with CellCept:</strong></p><p dir="ltr"><strong>&bull; If you have a sign of infection such as a fever or sore throat</strong></p><p dir="ltr"><strong>&bull; If you have any unexpected bruising or bleeding</strong></p><p dir="ltr"><strong>&bull; If you have ever had a problem with your digestive system such as a stomach ulcer</strong></p><p dir="ltr"><strong>&bull; If you are planning to become pregnant or if you get pregnant while you or partner are taking CellCept.</strong></p><p dir="ltr"><strong>If any of the above apply to you (or you are not sure), talk to your doctor straight away before starting treatment with CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The effect of sunlight</strong></p><p dir="ltr"><strong>CellCept reduces your body&rsquo;s defences. As a result, there is an increased risk of skin cancer. Limit the amount of sunlight and UV light you get. Do this by:</strong></p><p dir="ltr"><strong>&bull; wearing protective clothing that also covers your head, neck, arms and legs</strong></p><p dir="ltr"><strong>&bull; using a sunscreen with a high protection factor.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other medicines and CellCept</strong></p><p dir="ltr"><strong>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, such as herbal medicines. This is because CellCept can affect the way some other medicines work. Also other medicines can affect the way CellCept works.</strong></p><p dir="ltr"><strong>In particular, tell your doctor or pharmacist if you are taking any of the following medicines before you start CellCept:</strong></p><p dir="ltr"><strong>&bull; azathioprine or other medicines that suppress your immune system &ndash; given after a transplant operation</strong></p><p dir="ltr"><strong>&bull; cholestyramine &ndash; used to treat high cholesterol</strong></p><p dir="ltr"><strong>&bull; rifampicin &ndash; an antibiotic used to prevent and treat infections such as tuberculosis (TB)</strong></p><p dir="ltr"><strong>&bull; antacids or proton pump inhibitors &ndash; used for acid problems in your stomach such as indigestion</strong></p><p dir="ltr"><strong>&bull; phosphate binders &ndash; used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood.</strong></p><p dir="ltr"><strong>&bull; antibiotics &ndash; used to treat bacterial infections&nbsp;</strong></p><p dir="ltr"><strong>&bull; isavuconazole &ndash; used to treat fungal infections</strong></p><p dir="ltr"><strong>&bull; telmisartan &ndash; used to treat high blood pressure</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Vaccines</strong></p><p dir="ltr"><strong>If you need to have a vaccine (a live vaccine) while taking CellCept, talk to your doctor or pharmacist first. Your doctor will have to advise you on what vaccines you can have.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>You must not donate blood during treatment with CellCept and for at least 6 weeks after stopping treatment. Men must not donate semen during treatment with CellCept and for at least 90 days after stopping treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>CellCept with food and drink</strong></p><p dir="ltr"><strong>Taking food and drink has no effect on your treatment with CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy, contraception and breast-feeding</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Contraception in women taking CellCept</strong></p><p dir="ltr"><strong>If you are a woman who could become pregnant, you must use an effective method of contraception with CellCept. This includes:</strong></p><p dir="ltr"><strong>&bull; Before you start taking CellCept</strong></p><p dir="ltr"><strong>&bull; During your entire treatment with CellCept&nbsp;</strong></p><p dir="ltr"><strong>&bull; For 6 weeks after you stop taking CellCept.</strong></p><p dir="ltr"><strong>Talk to your doctor about the most suitable contraception for you. This will depend on your individual situation. Two forms of contraception are preferable as this will reduce the risk of unintended pregnancy. Contact your doctor as soon as possible, if you think your contraception may not have been effective or if you have forgotten to take your contraceptive pill.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>You are a woman who is not capable of becoming pregnant if any of the following applies to you:</strong></p><p dir="ltr"><strong>&bull; You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have had treatment for cancer, then there is still a chance you could become pregnant)</strong></p><p dir="ltr"><strong>&bull; Your fallopian tubes and both ovaries have been removed by surgery (bilateral&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; salpingo-oophorectomy)</strong></p><p dir="ltr"><strong>&bull; Your womb (uterus) has been removed by surgery (hysterectomy)</strong></p><p dir="ltr"><strong>&bull; Your ovaries no longer work (premature ovarian failure, which has been confirmed by a specialist gynaecologist)</strong></p><p dir="ltr"><strong>&bull; You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner&rsquo;s syndrome or uterine agenesis</strong></p><p dir="ltr"><strong>&bull; You are a child or teenager who has not started having periods.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Contraception in men taking CellCept</strong></p><p dir="ltr"><strong>The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, a risk cannot be completely excluded. As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking CellCept.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you are planning to have a child, talk to your doctor about the potential risks and alternative therapies.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr"><strong>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will talk to you about the risks in case of pregnancy and the alternatives you can take to prevent rejection of your transplant organ if:</strong></p><p dir="ltr"><strong>&bull; You plan to become pregnant.</strong></p><p dir="ltr"><strong>&bull; You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant.</strong></p><p dir="ltr"><strong>&bull; You have sex without using an effective method of contraception.</strong></p><p dir="ltr"><strong>If you do become pregnant during the treatment with mycophenolate, you must inform your doctor immediately. However, keep taking CellCept until you see him or her.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr"><strong>Mycophenolate causes a very high frequency of miscarriage (50%) and of severe birth defects (23 - 27&nbsp;%) in the unborn baby. Birth defects which have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed). Your baby may be affected by one or more of these.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor may request more than one test to ensure you are not pregnant before starting treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr"><strong>Do not take CellCept if you are breast-feeding. This is because small amounts of the medicine can pass into the mother&rsquo;s milk.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr"><strong>CellCept has a moderate influence on your ability to drive or use any tools or machines. If you feel drowsy, numb or confused, talk to your doctor or nurse and do not drive or use any tools or machines until you feel better.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Always take CellCept exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>How much to take</strong></p><p dir="ltr"><strong>The amount you take depends on the type of transplant you have had. The usual doses are shown below. Treatment will continue for as long as you need to prevent you from rejecting your transplant organ.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Kidney transplant</strong></p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>&bull; The first dose is given within 3 days of the transplant operation.</strong></p><p dir="ltr"><strong>&bull; The daily dose is 4 tablets (2&nbsp;g of the medicine) taken as 2 separate doses.&nbsp;</strong></p><p dir="ltr"><strong>&bull; Take 2 tablets in the morning and then 2 tablets in the evening.</strong></p><p dir="ltr"><strong>Children (aged 2 to 18 years)</strong></p><p dir="ltr"><strong>&bull; The dose given will vary depending on the size of the child.&nbsp;</strong></p><p dir="ltr"><strong>&bull; Your doctor will decide the most appropriate dose based on your child&rsquo;s height and weight (body surface area &ndash; measured as square metres or &ldquo;m2&rdquo;). The recommended dose is 600&nbsp;mg/m2 taken twice a day.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Heart transplant</strong></p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>&bull; The first dose is given within 5 days of the transplant operation.</strong></p><p dir="ltr"><strong>&bull; The daily dose is 6 tablets (3&nbsp;g of the medicine) taken as 2 separate doses.&nbsp;</strong></p><p dir="ltr"><strong>&bull; Take 3 tablets in the morning and then 3 tablets in the evening.</strong></p><p dir="ltr"><strong>Children</strong></p><p dir="ltr"><strong>&bull; There is no information for the use of CellCept in children with a heart transplant.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Liver transplant</strong></p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>&bull; The first dose of oral CellCept will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines.</strong></p><p dir="ltr"><strong>&bull; The daily dose is 6 tablets (3&nbsp;g of the medicine) taken as 2 separate doses.&nbsp;</strong></p><p dir="ltr"><strong>&bull; Take 3 tablets in the morning and then 3 tablets in the evening.&nbsp;</strong></p><p dir="ltr"><strong>Children</strong></p><p dir="ltr"><strong>&bull; There is no information for the use of CellCept in children with a liver transplant.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Taking the medicine</strong></p><p dir="ltr"><strong>&bull; Swallow your tablets whole with a glass of water.</strong></p><p dir="ltr"><strong>&bull; Do not break or crush them.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you take more CellCept than you should</strong></p><p dir="ltr"><strong>If you take more CellCept than you should, talk to a doctor or go to a hospital straight away. Also do this if someone else accidentally takes your medicine. Take the medicine pack with you.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you forget to take CellCept</strong></p><p dir="ltr"><strong>If you forget to take your medicine at any time, take it as soon as you remember. Then continue to take it at the usual times. Do not take a double dose to make up for a missed dose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you stop taking CellCept</strong></p><p dir="ltr"><strong>Do not stop taking CellCept unless your doctor tells you to. If you stop your treatment you may increase the chance of rejection of your transplanted organ.&nbsp;</strong></p><p dir="ltr"><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Like all medicines, CellCept can cause side effects, although not everybody gets them.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Talk to a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p dir="ltr"><strong>&bull; you have a sign of infection such as a fever or sore throat</strong></p><p dir="ltr"><strong>&bull; you have any unexpected bruising or bleeding</strong></p><p dir="ltr"><strong>&bull; you have a rash, swelling of your face, lips, tongue or throat, with difficulty breathing - you may be having a serious allergic reaction to the medicine (such as anaphylaxis, angioeodema).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Usual problems</strong></p><p dir="ltr"><strong>Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. Your doctor will do regular blood tests to check for any changes in:</strong></p><p dir="ltr"><strong>&bull; the number of your blood cells or signs of infections.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Children may be more likely than adults to have some side effects. These include diarrhoea, infections, fewer white cells and fewer red cells in the blood.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fighting infections</strong></p><p dir="ltr"><strong>CellCept reduces your body&rsquo;s defences. This is to stop you rejecting your transplant. As a result, your body will not be as good as normal at fighting infections. This means you may catch more infections than usual. This includes infections of the brain, skin, mouth, stomach and gut, lungs and urinary system.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Lymph and skin cancer</strong></p><p dir="ltr"><strong>As can happen in patients taking this type of medicine (immune-suppressants), a very small number of CellCept patients have developed cancer of the lymphoid tissues and skin.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>General unwanted effects</strong></p><p dir="ltr"><strong>You may get general side effects affecting your body as a whole. These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle), headache, flu symptoms and swelling.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other unwanted effects may include:</strong></p><p dir="ltr"><strong>Skin problems such as:&nbsp;</strong></p><p dir="ltr"><strong>&bull; acne, cold sores, shingles, skin growth hair loss, rash, itching.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Urinary problems such as:&nbsp;</strong></p><p dir="ltr"><strong>&bull; blood in the urine.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Digestive system and mouth problems such as:&nbsp;</strong></p><p dir="ltr"><strong>&bull; swelling of the gums and mouth ulcers,</strong></p><p dir="ltr"><strong>&bull; inflammation of the pancreas, colon or stomach,&nbsp;</strong></p><p dir="ltr"><strong>&bull; gastrointestinal disorders including bleeding,</strong></p><p dir="ltr"><strong>&bull; liver disorders&nbsp;</strong></p><p dir="ltr"><strong>&bull; diarrhea, constipation, feeling sick (nausea), indigestion, loss of appetite, flatulence.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Nervous system problems such as:&nbsp;</strong></p><p dir="ltr"><strong>&bull; feeling dizzy, drowsy or numb,&nbsp;</strong></p><p dir="ltr"><strong>&bull; tremor, muscle spasms, convulsions,&nbsp;</strong></p><p dir="ltr"><strong>&bull; feeling anxious or depressed, changes in your mood or thoughts.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Heart and blood vessel problems such as:</strong></p><p dir="ltr"><strong>&bull; change in blood pressure, accelerated heartbeat, widening of blood vessels.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Lung problems such as:&nbsp;</strong></p><p dir="ltr"><strong>&bull; pneumonia, bronchitis,&nbsp;</strong></p><p dir="ltr"><strong>&bull; shortness of breath, cough, which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung). Talk to your doctor if you develop a persistent cough or breathlessness,&nbsp;</strong></p><p dir="ltr"><strong>&bull; &nbsp; &nbsp; &nbsp; &nbsp; fluid on the lungs or inside the chest,</strong></p><p dir="ltr"><strong>&bull; sinus problems.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other problems such as:&nbsp;</strong></p><p dir="ltr"><strong>&bull; weight loss, gout, high blood sugar, bleeding, bruising.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of side effects</strong></p><p dir="ltr"><strong>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep this medicine out of the sight and reach of children.</strong></p><p dir="ltr"><strong>&bull; Do not use this medicine&nbsp; after the expiry date which is stated on the carton after EXP.</strong></p><p dir="ltr"><strong>&bull; Do not store above 30&deg;C.&nbsp;</strong></p><p dir="ltr"><strong>&bull; Keep in outer carton in order to protect from light.</strong></p><p dir="ltr"><strong>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br /></p><p dir="ltr"><strong>What CellCept film coated tablet contains</strong></p><p dir="ltr"><strong>&bull; The active substance is mycophenolate mofetil.</strong></p><p dir="ltr"><strong>&bull; The other ingredients are:</strong></p><p dir="ltr"><strong>&bull; CellCept tablets: microcrystalline cellulose, polyvidone (K-90), croscarmellose sodium, magnesium stearate</strong></p><p dir="ltr"><strong>&bull; tablet coating: hydroxypropyl methycellulose, hydroxypropyl cellulose, titanium dioxide (E171), polyethylene glycol 400, indigo carmine aluminium lake (E132), red iron oxide (E172).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CellCept tablets are lavender-coloured and caplet-shaped. They have “CellCept 500” engraved on one side and “Roche” on the other.
•	They are available as packs of 50 (in blister packs of 10) or Multipacks containing 150 (3 packs of 50) tablets.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,&nbsp;</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124</strong></p><p dir="ltr"><strong>CH-4070 Basel</strong></p><p dir="ltr"><strong>Switzerland.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in February 2020

To report any side effect(s):

Saudi Arabia:

The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
SFDA call center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc


 Other GCC States:
Please contact the relevant competent authority.


Council of Arab Health Ministers

This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
The doctor and the pharmacist are the experts in medicines, their benefits and risks.
Do not by yourself interrupt the period of treatment prescribed for you.
Do not repeat the same prescription without consulting your doctor.
Keep all medicaments out of reach of children.

Council of Arab Health Ministers
Union of Arab Pharmacists



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>الاسم الكامل للدواء هو سيلسيبت 500 ملغ أقراص مغلفة.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يستخدم في هذه النشرة الاسم الأقصر وهو سيلسيبت.</strong></p></li></ul><p dir="rtl"><strong>يحتوي سيلسيبت على ميكوفينولات موفيتيل.</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>ينتمي هذا الدواء إلى مجموعة من الأدوية تسمى &quot;مثبطات المناعة&quot;.</strong></p></li></ul><p dir="rtl"><strong>يستخدم سيلسيبت لمنع الجسم من رفض الأعضاء المزروعة.&nbsp;</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الكلى أو القلب أو الكبد.</strong></p></li></ul><p dir="rtl"><strong>يجب استخدام سيلسيبت مع أدوية أخرى:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>سيكلوسبورين وكورتيكوستيرويد.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><table><tbody><tr><td dir="ltr"><p dir="rtl"><strong>ما تحتاج إلى معرفته قبل تناول سيلسيبت</strong></p>&nbsp;<p dir="rtl"><strong>تحذير</strong></p>&nbsp;<p dir="rtl"><strong>تتسبب مادة ميكوفينولات في حدوث عيوب خلقية وإجهاض. إذا كان من يتناول هذا الدواء من النساء وكان من المحتمل أن تكون حاملاً، فيجب عليها أن تقدم اختبار حمل سلبي قبل بدء هذا العلاج ويجب اتباع الإرشادات الطبية لمنع الحمل التي يصفها الطبيب.</strong></p><p dir="rtl"><strong>سيتحدث معكِ طبيبِك ويعطيك معلومات مكتوبة، ولا سيما عن تأثيرات مادة ميكوفينولات على الأجنة. يرجى قراءة هذه المعلومات بعناية مع اتباع التعليمات.</strong></p><p dir="rtl"><strong>إذا لم تفهمي هذه الإرشادات بشكل كامل، فيرجى أن تطلبي من طبيبك توضيحها مرة أخرى وذلك قبل تناول مادة ميكوفينولات. راجعي أيضا مزيدا من المعلومات في هذه الفقرة تحت عنوان &quot;التحذيرات والاحتياطات&quot; و &quot;الحمل والرضاعة الطبيعية&quot;.</strong></p>&nbsp;<p dir="rtl"><strong>لا تتناول سيلسيبت:</strong></p>&nbsp;<ul><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من حساسية (شديدة) لمادة ميكوفينولات موفيتيل، أو حمض الميكوفينوليك أو أي من المكونات الأخرى في هذا الدواء (المذكورة في الفقرة 6)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كان من المحتمل أنك حامل ولم تقومي ﺑﺈﺟﺮاء ﻓﺤﺺ ﺳﻠﺒﻲ ﻟﻠﺤﻤﻞ ﻗﺒﻞ الوصفة الطبية الأولى، لأن مادة ميكوفينولات تتسبب في عيوب خلقية وإجهاض.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنتِ حاملاً أو تعتزمين للحمل أو تظنين أنك من المحتمل أن تكوني حاملاً</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنتِ لا تستخدمين وسائل فعالة لمنع الحمل (راجعي الحمل، ومنع الحمل والرضاعة الطبيعية).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت ترضعين طبيعياً.</strong></p></li></ul>&nbsp;<p dir="rtl"><strong>لا تناول هذا الدواء إذا كان أي من الحالات السابقة تنطبق عليك. وإذا لم تكوني متأكدة، فاستشيري طبيبك أو الصيدلي قبل تناول سيلسيبت.</strong></p>&nbsp;<p dir="rtl"><strong>التحذيرات والاحتياطات</strong></p><p dir="rtl"><strong>راجع طبيبك على الفور قبل بدء العلاج باستخدام سيلسيبت:&nbsp;</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; إذا كان لديك علامة على وجود عدوى مثل الحمى أو التهاب الحلق</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; إذا كنت تعاني من أي كدمات أو نزيف غير متوقع</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; إذا كنت قد عانيت سابقا من أي مشكلة في الجهاز الهضمي مثل قرحة المعدة</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; إذا كنت تخططين للحمل أو إذا كنت حاملاً أثناء تناولك أنت أو شريكك أقراص سيلسيبت.</strong></p>&nbsp;<p dir="rtl"><strong>إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك (أو لم تكن متأكدًا)، فراجع طبيبك على الفور قبل بدء العلاج باستخدام سيلسيبت.&nbsp;</strong></p>&nbsp;<p dir="rtl"><strong>تأثير أشعة الشمس</strong></p><p dir="rtl"><strong>يخفض سيلسيبت من القدرة الدفاعية المناعية بالجسم. ونتيجة لذلك، تبدو هناك خطورة متزايد من الإصابة بسرطان الجلد. لذا عليك الحد من كمية التعرض لأشعة الشمس والأشعة فوق البنفسجية التي تصل إليك. وافعل ذلك عن طريق:</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; &nbsp; ارتداء ملابس واقية تغطي رأسك ورقبتك وذراعيك وساقيك</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; &nbsp; استخدام كريم واقٍ من الشمس يحتوي بشكل مكثف على مادة تقي من أشعة الشمس.</strong></p>&nbsp;<p dir="rtl"><strong>تفاعل سيلسيبت مع الأدوية الأخرى</strong></p><p dir="rtl"><strong>يرجى مراجعة طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى. ويشمل ذلك أيا من الأدوية التي تناولتها دون وصفة طبية، مثل الأدوية العشبية. ذلك لأن سيلسيبت يمكن أن يؤثر على فعالية بعض الأدوية الأخرى. كما يمكن أن تؤثر الأدوية الأخرى على فعالية سيلسيبت.</strong></p><p dir="rtl"><strong>وبشكل خاص، استشر طبيبك أو الصيدلي إذا كنت تتناول أيا من الأدوية التالية قبل بدء تناول سيلسيبت:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>آزاثيوبرين أو أي أدوية أخرى تثبط جهاز المناعة لديك &ndash; توصف بعد إجراء عملية زرع أعضاء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>كوليسترامين - يستخدم لعلاج ارتفاع الكوليسترول</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ريفامبيسين - مضاد حيوي يستخدم لمنع وعلاج الالتهابات مثل السل (TB)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مضادات الحموضة أو مثبطات مضخات البروتون - تستخدم لمشكلات الحمض في المعدة مثل عسر الهضم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>رابطات الفوسفات &ndash; يستخدمها الأشخاص الذين يعانون من الفشل الكلوي المزمن لتقليل كمية امتصاص الفوسفات في دمائهم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>المضادات الحيوية - تستخدم لعلاج الالتهابات البكتيرية</strong></p></li><li dir="rtl"><p><strong>ايزافوكونازول&nbsp;- يستخدم لعلاج الالتهابات الفطرية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تلميسارتان - يستخدم لعلاج ارتفاع ضغط الدم</strong></p></li></ul>&nbsp;<p dir="rtl"><strong>اللقاحات</strong></p><p dir="rtl"><strong>إذا كنت بحاجة إلى لقاح (لقاح حي) أثناء تناول سيلسيبت، استشر طبيبك أو الصيدلي أولاً. سيتعين على طبيبك توجيهك بشأن اللقاحات التي يمكنك الحصول عليها.</strong></p><p dir="rtl"><strong>يجب عليك عدم التبرع بالدم أثناء العلاج باستخدام سيلسيبت ولمدة 6 أسابيع على الأقل بعد انتهاء العلاج به. يجب على الرجال عدم التبرع بالمني أثناء العلاج باستخدام سيلسيبت ولمدة 90 يومًا على الأقل بعد انتهاء العلاج.</strong></p>&nbsp;<p dir="rtl"><strong>تفاعل سيلسيبت مع الطعام والشراب</strong></p>&nbsp;<p dir="rtl"><strong>تناول الطعام والشراب ليس له أي تأثير على علاجك مع سيلسيبت.</strong></p>&nbsp;<p dir="rtl"><strong>الحمل، ومنع الحمل والرضاعة &ndash; الطبيعية</strong></p>&nbsp;<p dir="rtl"><strong>منع الحمل لدى النساء اللاتي يتناولن سيلسيبت</strong></p><p dir="rtl"><strong>إذا كنت امرأة يمكن أن تصبح حاملاً، يجب عليك استخدام وسيلة فعالة لمنع الحمل مع سيلسيبت،وهذا يشمل الآتي:</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; قبل البدء في تناول سيلسيبت</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; خلال فترة علاجكِ باستخدام سيلسيبت بأكملها</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; لمدة 6 أسابيع بعد الانتهاء من تناول سيلسيبت.</strong></p>&nbsp;<p dir="rtl"><strong>استشيري طبيبكِ حول وسائل منع الحمل الأنسب لكِ. وهذا يعتمد على ظروفك الشخصية. يُفضل استخدام نوعين من وسائل منع الحمل لأن هذا سيقلل من مخاطر الحمل غير المقصود. وراجعي طبيبكِ في أقرب وقت ممكن، إذا كنتِ تعتقدين أن وسائل منع الحمل قد لا تكون فعالة أو إذا نسيتِ تناول حبوب منع الحمل.</strong></p>&nbsp;<p dir="rtl"><strong>لا يمكنكِ الحمل إذا انطبق عليك أي من الأمور التالية:</strong></p><p dir="rtl"><strong>&bull; &nbsp; إذا كنت في مرحلة ما بعد انقطاع الطمث، مثلاً سنك تقل عن 50 عامًا وكانت الدورة الأخيرة لك قد مضى عليها أكثر من عام (إذا كانت الدورة قد توقفت بسبب تناولكِ علاجًا للسرطان، فلا يزال هناك احتمال أن تصبحي حاملاً)</strong></p><p dir="rtl"><strong>&bull; &nbsp; إذا تمت إزالة قناتي فالوب وكلا المبيضين عن طريق الجراحة (استئصال البوق والمبيض الثنائي)</strong></p><p dir="rtl"><strong>&bull; &nbsp; إذا تمت إزالة رحمك عن طريق الجراحة (استئصال الرحم)</strong></p><p dir="rtl"><strong>&bull; &nbsp; إذا توقف المبيض عن العمل (فشل المبيض المبكر، بعد تأكيد أخصائي أمراض النساء لذلك)</strong></p><p dir="rtl"><strong>&bull; &nbsp; إذا وُلدت بواحدة من الحالات النادرة التالية التي تجعل الحمل مستحيلاً: النمط الوراثي (XY)، أو متلازمة تيرنر أو التهاب الرحم.</strong></p><p dir="rtl"><strong>&bull; &nbsp; إذا كنتِ طفلة أو مراهقة ولم يبدأ حدوث الطمث بعد.</strong></p>&nbsp;<p dir="rtl"><strong>منع الحمل بالنسبة للرجال الذين يتناولون سيلسيبت</strong></p>&nbsp;<p dir="rtl"><strong>لا تشير الأدلة المتاحة إلى زيادة خطر حدوث تشوهات أو إجهاض إذا أخذ الأب عقار ميكوفينولات. ومع ذلك، لا يمكن استبعاد الخطر تماما. كإجراء وقائي، يُنصح أنت أو شريكتك باستخدام وسائل منع الحمل الموثوقة أثناء العلاج ولمدة تسعون (90) يومًا بعد التوقف عن تناول سيلسيبت.&nbsp;</strong></p>&nbsp;<p dir="rtl"><strong>إذا كنت تخطط لإنجاب طفل، فتحدث إلى طبيبك حول المخاطر المحتملة والعلاجات البديلة.</strong></p>&nbsp;<p dir="rtl"><strong>الحمل والرضاعة الطبيعية</strong></p>&nbsp;<p dir="rtl"><strong>إذا كنت حاملاً أو مرضِعا، أو تظنين أنك قد تكونين حاملاً أو تعتزمين إنجاب طفل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء. سيخبركِ طبيبك عن مخاطر الحمل والبدائل التي يمكنك اتخاذها لمنع رفض العضو المزروع لديك، وذلك في الحالات التالية:&nbsp;</strong></p><p dir="rtl"><strong>&nbsp;&bull; &nbsp; اعتزامك الحمل.</strong></p><p dir="rtl"><strong>&bull;&nbsp; &nbsp; إذا فاتتك الدورة أو اعتقدتِ ذلك، أو إذا عانيتِ من نزيف غير عادي في الحيض، أو شككتِ في حدوث الحمل.<br />&bull;&nbsp; &nbsp; ممارسة الجنس دون استخدام وسيلة فعالة لمنع الحمل.</strong><br />&nbsp;</p><p dir="rtl"><strong>يجب عليك إبلاغ طبيبك على الفور إذا أصبحت حاملاً خلال فترة العلاج باستخدام ميكوفينولات. ومع ذلك، استمري في تناول سيلسيبت حتى تستشيريه.<br /><br />الحمل<br />تسبب&nbsp; مادة ميكوفينولات معدلات كبيرة للإجهاض (50%) والعيوب الخلقية الشديدة (23-27%) في الجنين. تشمل العيوب الخلقية التي تم الإبلاغ عنها اختلالات الأذنين والعينين والوجه (الشفة المشقوقة / الحنك)، ونمو الأصابع، والقلب، والمريء (الأنبوب الذي يربط الحلق مع المعدة)، والكلى والجهاز العصبي (على سبيل المثال السنسنة المشقوقة (حيث لا تنمو عظام العمود الفقري بشكل صحيح). قد يتأثر طفلك بواحد أو أكثر من هذه العيوب والاختلالات.<br /><br />إذا كان&nbsp; من يتعاطى العقار امرأة، وكان من المحتمل أنها حامل ، فيجب عليها أن تقدم اختبار حمل سلبي قبل بدء العلاج ويجب عليها اتباع نصيحة منع الحمل التي يقدمها لها الطبيب. وقد يطلب الطبيب أكثر من اختبار للتأكد من أنكِ لستِ حاملاً قبل بدء العلاج.</strong></p>&nbsp;<p dir="rtl"><strong>الرضاعة الطبيعية<br />لا تتناولي سيلسيبت إذا كنتِ مرضِعا. وذلك لأن كميات صغيرة من الدواء يمكن أن تصل في حليب الأم.<br /><br />القيادة واستخدام الآلات<br />سيلسيبت له تأثير معتدل على قدرتك على القيادة أو استخدام أي أدوات أو آلات.&nbsp;إذا شعرت بالنعاس أو الخدر أو التشويش، تحدث إلى طبيبك أو ممرضك ولا تقود أو تستخدم أي أدوات أو آلات حتى تشعر بالتحسن.</strong></p>&nbsp;<p dir="rtl"><strong>يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملي جرام) لكل قرص، وهذا يعني بشكل أساسي &quot;خالي من الصوديوم&quot;.<br />&nbsp;</strong></p></td></tr><tr><td dir="ltr"><p dir="rtl"><br />&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><table><tbody><tr><td dir="ltr"><p dir="rtl"><strong>3.</strong></p></td><td dir="ltr"><p dir="rtl"><strong>كيفية تناول سيلسيبت<br /><br />تناول سيلسيبت تماما كما وصفه لك طبيبك. ويجب عليك مراجعة طبيبك أو الصيدلي إذا كنت غير واثق من أي شيء.<br /><br />الجرعة<br />تعتمد الكمية التي تتناولها على نوع العضو المزروع لك. الجرعات المعتادة موضحة أدناه. ويستمر العلاج ما دمت بحاجة لمنع رفض العضو المزروع.<br /><br />زراعة الكلى<br />الكبار<br />&bull;&nbsp; &nbsp; تعطى الجرعة الأولى خلال فترة 5 أيام من عملية الزرع.<br />&bull;&nbsp; &nbsp; الجرعة اليومية هي 6 أقراص (3 جرامات من الدواء) تؤخذ على جرعتين منفصلتين.<br />&bull;&nbsp; &nbsp; تناول 3 أقراص في الصباح قرصين اثنين في المساء.<br />&bull;&nbsp; &nbsp; الأطفال (من عمر عامين إلى 18 عامًا)<br />&bull;&nbsp; &nbsp; تختلف الجرعة المحددة حسب حجم الطفل.<br />&nbsp; &bull; سيقرر الطبيب أنسب جرعة بناءً على طول ووزن طفلك (مساحة سطح الجسم - تقاس كمتر المربع أو &quot;m2) الجرعة الموصى بها هي 600 مجم / م 2 تؤخذ مرتين في اليوم.<br /><br />زراعة القلب<br />الكبار<br />&bull; يتم إعطاء الجرعة الأولى في غضون 5 أيام من عملية الزرع.<br />&bull; الجرعة اليومية هي 6 أقراص (3 جرامات من الدواء) تؤخذ على جرعتين منفصلتين.<br />&bull; تناول 3 أقراص في الصباح ثم 3 أقراص أخرى في المساء.<br /><br />الأطفال</strong></p><p dir="rtl"><br /><strong>&bull; لا توجد معلومات لاستخدام سيلسيبت مع الأطفال الذين خضعوا لزراعة قلب.</strong></p></td></tr></tbody></table><p dir="rtl"><strong>زراعة الكبد<br />الكبار<br />&bull; سيتم إعطاء الجرعة الأولى من سيلسيبت عن طريق الفم بعد 4 أيام على الأقل من عملية الزرع وعندما تتمكن من ابتلاع الأدوية الفموية.<br />&bull; الجرعة اليومية هي 6 أقراص (3 جرامات من الدواء) تؤخذ على جرعتين منفصلتين.<br />&bull; تناول 3 أقراص في الصباح و 3 أقراص في المساء.<br /><br />الأطفال<br />&bull; لا توجد معلومات بالنسبة لاستخدام سيلسيبت مع الأطفال الذين خضعوا لزراعة كبد.<br /><br />تناول الدواء</strong></p><p><br /><strong>&bull; ابتلع أقراصك كاملة مع كوب من الماء.<br />&bull; لا تكسرها أو تسحقها.<br /><br />الإفراط في تناول سيلسيبت<br />إذا تناولت سيلسيبت أكثر من الجرعة الموصى بها، فراجع الطبيب أو توجه لأقرب مستشفى على الفور. وينبغي عليك أيضاً القيام بذلك إذا كان هناك شخص آخر قد تناول الدواء الخاص بك عن طريق الخطأ. وأحضر معك علبة الدواء<br /><br />إذا نسيت تناول سيلسيبت<br />إذا نسيت تناول الدواء الخاص بك في أي وقت، فعليك بتناوله بمجرد أن تتذكر ذلك. ثم استمر في تناول الدواء في الأوقات المعتادة. ولا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.<br /><br />إذا توقفت عن تناول سيلسيبت<br />لا تتوقف عن تناول سيلسيبت ما لم يخبرك طبيبك بذلك. لأنك إذا توقفت عن تناول علاجك فقد تزيد من فرص رفض العضو المزروع.<br />راجع طبيبك أو الصيدلي إذا كان لديك أي استفسارات أخرى.</strong><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><table><tbody><tr><td dir="ltr"><p dir="rtl"><strong>4.</strong></p></td><td dir="ltr"><p dir="rtl"><strong>الآثار الجانبية المحتملة</strong></p>&nbsp;<p dir="rtl"><strong>كما هو الحال في جميع الأدوية، فيمكن أن يسبب سيلسيبت آثارا جانبية، على الرغم من إمكانية عدم إصابة الجميع بها.</strong></p></td></tr></tbody></table><p dir="rtl"><strong>راجع الطبيب فورًا إذا لاحظت أيًا من الأعراض الجانبية الخطيرة التالية &ndash; والتي قد تحتاج إلى تدخل طبي عاجل:<br />&nbsp; &bull;&nbsp; أن تظهر عليك علامة العدوى مثل الحمى أو التهاب الحلق<br />&bull;&nbsp; &nbsp; أن تظهر عليك أي كدمات أو نزيف غير متوقع<br />&nbsp; &nbsp; &bull; أن تتعرض لطفح جلدي، أو تورم في وجهك، أو الشفتين، أو اللسان أو الحلق ، مع صعوبة في التنفس - قد يكون لديك حساسية&nbsp; شديدة من الدواء (مثل الحساسية المفرطة، الوذمة الوعائية).<br /><br />الأعراض المعتادة</strong></p><p dir="rtl"><br /><strong>بعض من الأعراض الأكثر شيوعاً تشمل الإسهال، وعدد أقل من الخلايا البيضاء أو الخلايا الحمراء في الدم والالتهابات والقيء. يقوم الطبيب بإجراء فحوصات دم منتظمة للتحقق من وجود أي تغييرات في:<br />&bull;&nbsp; &nbsp; عدد خلايا الدم لديك أو علامات العدوى.</strong></p><p dir="rtl"><br /><strong>قد يكون الأطفال أكثر عرضة للإصابة بالأعراض الجانبية من البالغين. ويشمل هذا الإسهال، والالتهابات، وعدد أقل من الخلايا البيضاء والخلايا الحمراء في الدم.</strong></p><p><br />&nbsp;</p><p dir="rtl"><strong>مكافحة العدوى</strong></p><p dir="rtl"><strong>يقلل دواء سيلسيبت من الدفاعات المناعية بالجسم لديك. ويهدف بهذا الأمر منع رفض جسمك للعضو المزروع في جسدك. ونتيجة لذلك، لن يكون جسمك في وضعه الطبيعي فيما يتعلق بمكافحة العدوى. ويعني ذلك أنك قد تصاب بعدوى بصورة أكثر من المعتاد، ويشمل ذلك بطبيعة الحال إصابات الدماغ والجلد والفم والمعدة والأمعاء والرئتين والجهاز البولي.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>سرطان الغدد الليمفاوية والجلد</strong></p><p dir="rtl"><strong>في الوقت الذي يمكن أن يحدث للمرضى الذين يتناولون أدوية من هذا النوع (الأدوية المثبطة للمناعة)، فإن عددا صغيرا جدا من المرضى الذين يستعملون سيلسيبت أصيبوا بسرطان الغدد اللمفاوية والجلد.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>آثار عامة غير مرغوب فيها.</strong></p><p dir="rtl"><strong>قد تحصل لك آثار جانبية عامة تؤثر على جسمك بأكمله. يشمل ذلك ردود الفعل التحسسية الحادة (مثل الحساسية المفرطة، والوذمة الوعائية) والحمى والشعور بالإرهاق الشديد وصعوبة النوم والآلام (مثل آلام المعدة والصدر والمفاصل أو العضلات) والصداع وأعراض الانفلونزا والتورم.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>قد تتضمن الآثار غير المرغوب فيها الأخرى ما يلي:</strong></p><p dir="rtl"><strong>مشاكل جلدية مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>حب الشباب والقروح الباردة والهربس النطاقي (الحزام الناري) والزوائد الجلدية وتساقط الشعر والطفح الجلدي والحكة.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>مشاكل في المسالك البولية مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>دم في البول.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>مشاكل الجهاز الهضمي والفم مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>تورم اللثة وقرح الفم،</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب البنكرياس أو القولون أو المعدة،</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشاكل في القناة الهضمية بما في ذلك النزيف&nbsp;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اضطرابات الكبد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإسهال، الإمساك والشعور بالتعب (الغثيان) وعسر الهضم وفقدان الشهية وانتفاخ البطن.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>مشاكل في الجهاز العصبي مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الشعور بالدوار أو النعاس أو الخدر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ارتجاف وتشنجات عضلية واختلاجات،</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالقلق أو الاكتئاب وتغيرات في مزاجك أو أفكارك.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>مشاكل القلب والأوعية الدموية مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>تغير في ضغط الدم وتسارع ضربات القلب واتساع الأوعية الدموية.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>مشاكل في الرئة مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الالتهاب الرئوي والتهاب الشعب الهوائية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضيق التنفس والسعال الذي يمكن أن يكون بسبب تمدد الشعب الهوائية (وهي حالة يكون فيها مجرى الهواء الرئوي متسعاً بشكل غير طبيعي) أو التليف الرئوي (تقرح في الرئة). استشر طبيبك إذا كنت تعاني من سعال مستمر أو ضيق في التنفس.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سوائل في الرئتين أو في الصدر.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشاكل الجيوب الأنفية.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>مشاكل أخرى مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>فقدان الوزن والنقرس وارتفاع نسبة السكر في الدم والنزيف والكدمات.</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>الإبلاغ عن الآثار الجانبية</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>في حالة حدوث أي آثار جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي آثار جانبية غير مذكورة في هذه النشرة. عن طريق الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl"><p dir="rtl"><strong>يحفظ بعيدًا عن متناول ورؤية الأطفال.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية المحددة على العلبة (بعد كلمة EXP).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>لا تخزن الدواء في درجة حرارة أعلى من 30 درجة مئوية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>احتفظ بالدواء داخل الكرتون الخارجي لحمايته من الضوء.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>يجب عدم التخلص من الأدوية بإلقائها في المجاري أو النفايات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. تساعد هذه التدابير على حماية البيئة.</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>ما يحتوي عليه قرص سيلسيبت المغلف&nbsp;</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>المادة الفعالة هي ميكوفينولات موفيتيل.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>المكونات الأخرى هي:</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أقراص سيلسيبت: سليلوز دقيق التبلور وبوليفيدون (K-90) وكروس كارميلوز الصوديوم وستيارات الماغنيسيوم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>غلاف القرص: هيدروكسي بروبيل ميثيل سيللوز، وهيدروكسي بروبيل السيللوز، وثنائي أكسيد التيتانيوم (E171)، وبولي إيثيلين جلايكول 400، وإنديجو كارمن ألومنيوم (E132)، وأكسيد الحديد الأحمر (E172).</strong></p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شكل ومحتويات عبوة سيلسيبت</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>أقراص سيلسيبت أرجوانية اللون وعلى شكل كبسولة. ومحفور عليها كلمة &quot; CellCept 500&quot; من جانب واحد و &quot;Roche&quot; من الجانب الآخر.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تتوفر على شكل علب تحتوي على 50 قرصا (10 أقراص في كل شريط) أو حزم متعددة تحتوي على 150 قرص (3 عبوات من 50 قرص).</strong></p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>إف. هوفمان &ndash; لا روش المحدودة،</strong></p><p dir="rtl"><strong>124 جرينزاشيرستراس،</strong></p><p dir="rtl"><strong>سي إتش &ndash; 4070 بازل،</strong></p><p dir="rtl"><strong>سويسرا.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ فبراير 2020

للإبلاغ عن أي آثار جانبية:

المملكة العربية السعودية:

المركز الوطني للتيقظ والسلامة الدوائية (NPC)
فاكس: 966112057662+
هاتف: 2038222 - 11 - 966 + داخلي: 2317 – 2356 – 234 
مركز اتصالات الهيئة العامة للغذاء والدواء: 19999
البريد الإلكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: www.sfda.gov.sa/npc


دول مجلس التعاون الخليجي الأخرى:

يرجى الاتصال بالهيئة المختصة ذات الصلة.



مجلس وزراء الصحة العرب

هذا الدواء
- هذا الدواء منتج يؤثر على صحتك واستهلاكه بطريقة مخالفة للتعليمات يعرض حياتك للخطر.
- اتبع إرشادات الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء.
- الطبيب والصيدلي هم خبراء في الأدوية وفوائدها ومخاطرها.
- لا تتوقف من تلقاء نفسك عن العلاج الموصوف لك.
- لا تكرر نفس الوصفة الطبية من تلقاء نفسك دور استشارة الطبيب.
- تحفظ جميع الأدوية بعيدا عن متناول الأطفال.

مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CellCept 500 mg film-coated tablets.
BLACK BOX WARNING
EMBRYOFETAL TOXICITY, MALIGNANCIES AND SERIOUS INFECTIONS
Use during pregnancy is associated with increased risks of first trimester pregnancy loss
and congenital malformations. Females of reproductive potential (FRP) must be
counseled regarding pregnancy prevention and planning (see Immunosuppression may
lead to increased susceptibility to infection and possible development of lymphoma.
Only physicians experienced in immunosuppressive therapy and management of renal,
cardiac or hepatic transplant patients should prescribe CellCept. Patients receiving the
drug should be managed in facilities equipped and staffed with adequate laboratory and
supportive medical resources. The physician responsible for maintenance therapy should
have complete information requisite for the follow-up of the patient.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 500 mg mycophenolate mofetil.

Excipient(s) with known effect

Sodium less than 1 mmol (23 mg) per dose

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets (tablets).

CellCept tablets: lavender-coloured caplet-shaped tablet, engraved with "CellCept 500" on one side and "Roche" on the other. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Treatment with CellCept should be initiated and maintained by appropriately qualified transplant specialists.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Posology</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use in renal transplant</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>Oral CellCept should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1&nbsp;g administered twice daily (2&nbsp;g daily dose).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population aged 2 to 18 years</strong></p><p dir="ltr"><strong>The recommended dose of mycophenolate mofetil is 600&nbsp;mg/m2 administered orally twice daily (up to a maximum of 2&nbsp;g daily). CellCept tablets should only be prescribed to patients with a body surface area greater than 1.5&nbsp;m2, at a dose of 1&nbsp;g twice daily (2&nbsp;g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population &lt;&nbsp;2 years</strong></p><p dir="ltr"><strong>There are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use in cardiac transplant&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>Oral CellCept should be initiated within 5 days following transplantation. The recommended dose in cardiac transplant patients is 1.5&nbsp;g administered twice daily (3&nbsp;g daily dose).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>No data are available for paediatric cardiac transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use in hepatic transplant</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adults</strong></p><p dir="ltr"><strong>IV CellCept should be administered for the first 4 days following hepatic transplant, with oral CellCept initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5&nbsp;g administered twice daily (3&nbsp;g daily dose).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population&nbsp;</strong></p><p dir="ltr"><strong>No data are available for paediatric hepatic transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use in special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly&nbsp;</strong></p><p dir="ltr"><strong>The recommended dose of 1&nbsp;g administered twice a day for renal transplant patients and 1.5&nbsp;g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p dir="ltr"><strong>In renal transplant patients with severe chronic renal impairment (glomerular filtration rate &lt;&nbsp;25&nbsp;ml/min/1.73&nbsp;m2), outside the immediate post-transplant period, doses greater than 1&nbsp;g administered twice a day should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively (see section 5.2). No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Severe hepatic impairment</strong></p><p dir="ltr"><strong>No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Treatment during rejection episodes</strong></p><p dir="ltr"><strong>Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of CellCept is not required. There is no basis for CellCept dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>No data are available for treatment of first or refractory rejection in paediatric transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Method of administration</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Oral administration.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Precautions to be taken before handling or administering the medicinal product.</strong></p><p dir="ltr"><strong>Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, CellCept tablets should not be crushed.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CellCept should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. Hypersensitivity reactions to CellCept have been observed (see section 4.8). 

•	CellCept should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6). 

•	CellCept treatment should not be initiated in women of childbearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6).

•	CellCept should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).

•	CellCept should not be given to women who are breastfeeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Neoplasms</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As general advice to minimise the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients treated with immunosuppressants, including CellCept, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). Such infections include latent viral reactivation, such as hepatitis B or hepatitis C reactivation and infections caused by polyomaviruses (BK virus-associated nephropathy, JC virus-associated progressive multifocal leukoencephalopathy PML). Cases of hepatitis due to reactivation of hepatitis B or hepatitis C have been reported in carrier patients treated with immunosuppressants. These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving CellCept in combination with other immunosuppressants. In some of these cases switching CellCept to an alternative immunosuppressant resulted in serum IgG levels returning to normal. Patients on CellCept who develop recurrent infections should have their serum immunoglobulins measured. In cases of sustained, clinically relevant hypogammaglobulinaemia, appropriate clinical action should be considered taking into account the potent cytostatic effects that mycophenolic acid has on T- and B-lymphocytes.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>There have been published reports of bronchiectasis in adults and children who received CellCept in combination with other immunosuppressants. In some of these cases switching CellCept to another immunosuppressant resulted in improvement in respiratory symptoms. The risk of bronchiectasis may be linked to hypogammaglobulinaemia or to a direct effect on the lung. There have also been isolated reports of interstitial lung disease and pulmonary fibrosis, some of which were fatal (see section 4.8). It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Blood and immune system</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients receiving CellCept should be monitored for neutropenia, which may be related to CellCept itself, concomitant medications, viral infections, or some combination of these causes. Patients taking CellCept should have complete blood counts weekly during the first month, twice monthly for the second and third months of treatment, then monthly through the first year. If neutropenia develops (absolute neutrophil count &lt;&nbsp;1.3 x 103/&micro;l), it may be appropriate to interrupt or discontinue CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with CellCept in combination with other immunosuppressants. The mechanism for mycophenolate mofetil induced PRCA is unknown. PRCA may resolve with dose reduction or cessation of CellCept therapy. Changes to CellCept therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients receiving CellCept should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow failure.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients should be advised that, during treatment with CellCept, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5). Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gastro-intestinal</strong></p><p>&nbsp;</p><p dir="ltr"><strong>CellCept has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation. CellCept should be administered with caution in patients with active serious digestive system disease.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>CellCept is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Interactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation, e.g. ciclosporin, to others devoid of this effect, e.g. tacrolimus, sirolimus, belatacept, or vice versa, as this might result in changes of MPA exposure. Drugs which interfere with MPA&rsquo;s enterohepatic cycle (e.g. cholestyramine, antibiotics) should be used with caution due to their potential to reduce the plasma level and efficacy of CellCept (see also section 4.5). Therapeutic drug monitoring of MPA may be appropriate when switching combination therapy (e.g. from ciclosporin to tacrolimus or vice versa) or to ensure adequate immunosuppression in patients with high immunological risk (e.g. risk of rejection, treatment with antibiotics, addition or removal of an interacting medication).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>It is recommended that CellCept should not be administered concomitantly with azathioprine because such concomitant administration has not been studied.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The risk/benefit ratio of mycophenolate mofetil in combination with sirolimus has not been established (see also section 4.5).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly patients may be at an increased risk of adverse events such as certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals (see section 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Teratogenic effects</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mycophenolate is a powerful human teratogen. Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy. Therefore, CellCept is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection. Female patients of childbearing potential should be made aware of the risks and follow the recommendations provided in section 4.6 (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with CellCept. Physicians should ensure that women taking mycophenolate understand the risk of harm to the baby, the need for effective contraception, and the need to immediately consult their physician if there is a possibility of pregnancy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Contraception (see section 4.6)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Because of robust clinical evidence showing a high risk of abortion and congenital malformations when mycophenolate mofetil is used in pregnancy, every effort to avoid pregnancy during treatment should be taken. Therefore, women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting CellCept therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred to minimise the potential for contraceptive failure and unintended pregnancy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For contraception advice for men see section 4.6.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Educational materials</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In order to assist patients in avoiding foetal exposure to mycophenolate and to provide additional important safety information, the Marketing Authorisation Holder will provide educational materials to healthcare professionals. The educational materials will reinforce the warnings about the teratogenicity of mycophenolate, provide advice on contraception before therapy is started and guidance on the need for pregnancy testing. Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Additional precautions</strong></p><p dir="ltr"><strong>Patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate. Men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Aciclovir</strong></p><p dir="ltr"><strong>Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone. The changes in MPAG (the phenolic glucuronide of MPA) pharmacokinetics (MPAG increased by 8%) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its prodrugs, e.g. valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Antacids and proton pump inhibitors (PPIs)</strong></p><p dir="ltr"><strong>Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with CellCept. When comparing rates of transplant rejection or rates of graft loss between CellCept patients taking PPIs vs. CellCept patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when CellCept was co- administered with magnesium and aluminium hydroxides is considerably less than when CellCept was co-administered with PPIs.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Medicinal products that interfere with enterohepatic recirculation (e.g. cholestyramine, ciclosporin A,&nbsp;</strong></p><p dir="ltr"><strong>antibiotics)</strong></p><p dir="ltr"><strong>Caution should be used with medicinal products that interfere with enterohepatic recirculation because of their potential to reduce the efficacy of CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cholestyramine</strong></p><p dir="ltr"><strong>Following single dose administration of 1.5&nbsp;g of mycophenolate mofetil to normal healthy subjects pre-treated with 4&nbsp;g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2). Caution should be used during concomitant administration because of the potential to reduce efficacy of CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Ciclosporin A</strong></p><p dir="ltr"><strong>Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.</strong></p><p dir="ltr"><strong>In contrast, if concomitant CsA treatment is stopped, an increase in MPA AUC of around 30% should be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30 - 50% in renal transplant patients treated with CellCept and CsA compared with patients receiving sirolimus or belatacept and similar doses of CellCept (see also section 4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the immunosuppressants which does not interfere with MPA&rsquo;s enterohepatic cycle.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Antibiotics eliminating &reg;-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antibiotics) may interfere with MPAG/MPA enterohepatic recirculation, thus leading to reduced systemic MPA exposure. Information concerning the following antibiotics is available:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Ciprofloxacin or amoxicillin plus clavulanic acid</strong></p><p dir="ltr"><strong>Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of CellCept should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Norfloxacin and metronidazole</strong></p><p dir="ltr"><strong>In healthy volunteers, no significant interaction was observed when CellCept was concomitantly administered with norfloxacin or metronidazole separately. However, norfloxacin and metronidazole combined reduced the MPA exposure by approximately 30% following a single dose of CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Trimethoprim/sulfamethoxazole</strong></p><p dir="ltr"><strong>No effect on the bioavailability of MPA was observed.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan)</strong></p><p dir="ltr"><strong>Concomitant administration of drugs affecting glucuronidation of MPA may change MPA exposure. Caution is therefore recommended when administering these drugs concomitantly with CellCept.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Isavuconazole</strong></p><p dir="ltr"><strong>An increase of MPA AUC0-&infin; by 35% was observed with concomitant administration of isavuconazole.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Telmisartan</strong></p><p dir="ltr"><strong>Concomitant administration of telmisartan and CellCept resulted in an approximately 30% decrease of MPA concentrations. Telmisartan changes MPA&rsquo;s elimination by enhancing PPAR&nbsp;gamma (peroxisome proliferator-activated receptor&nbsp;gamma) expression, which in turn results in an enhanced UGT1A9 expression and activity. When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between CellCept patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Ganciclovir</strong></p><p dir="ltr"><strong>Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of CellCept (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and CellCept dose adjustment is not required. In patients with renal impairment in whom CellCept and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered, the dose recommendations for ganciclovir should be observed and patients should be monitored carefully.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Oral contraceptives</strong></p><p dir="ltr"><strong>The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co-administration of CellCept (see also section 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Rifampicin</strong></p><p dir="ltr"><strong>In patients not also taking ciclosporin, concomitant administration of CellCept and rifampicin resulted in a decrease in MPA exposure (AUC0-12h) of 18% to 70%. It is recommended to monitor MPA exposure levels and to adjust CellCept doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Sevelamer</strong></p><p dir="ltr"><strong>Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when CellCept was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). It is recommended, however, to administer CellCept at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA. There are no data on CellCept with phosphate binders other than sevelamer.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tacrolimus</strong></p><p dir="ltr"><strong>In hepatic transplant patients initiated on CellCept and tacrolimus, the AUC and Cmax of MPA, the active metabolite of CellCept, were not significantly affected by co-administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of CellCept (1.5&nbsp;g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by CellCept (see also section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Live vaccines</strong></p><p dir="ltr"><strong>Live vaccines should not be given to patients with an impaired immune response. The antibody response to other vaccines may be diminished (see also 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>Interaction studies have only been performed in adults.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Potential interaction</strong></p><p dir="ltr"><strong>Co-administration of probenecid with mycophenolate mofetil in monkeys raises plasma AUC of MPAG by 3-fold. Thus, other substances known to undergo renal tubular secretion may compete with MPAG, and thereby raise plasma concentrations of MPAG or the other substance undergoing tubular secretion.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Women of childbearing potential</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy whilst taking mycophenolate must be avoided. Therefore, women of childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting CellCept therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong></p><p>&nbsp;</p><p dir="ltr"><strong>CellCept is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy (see section 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Female patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counselled regarding pregnancy prevention and planning.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Before starting CellCept treatment, women of childbearing potential should have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/ml in order to exclude unintended exposure of the embryo to mycophenolate. It is recommended that the second test should be performed 8 - 10 days after the first test. For transplants from deceased donors, if it is not possible to perform two tests 8 - 10 days apart before treatment starts (because of the timing of transplant organ availability), a pregnancy test must be performed immediately before starting treatment and a further test performed 8 - 10 days later. Pregnancy tests should be repeated as clinically required (e.g. after any gap in contraception is reported. Results of all pregnancy tests should be discussed with the patient. Patients should be instructed to consult their physician immediately should pregnancy occur.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mycophenolate is a powerful human teratogen, with an increased risk of spontaneous abortions and congenital malformations in case of exposure during pregnancy;</strong></p><p dir="ltr"><strong>&bull; Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil.</strong></p><p dir="ltr"><strong>&bull; Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3% of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Congenital malformations, including reports of multiple malformations, have been observed post-marketing in children of patients exposed to CellCept during pregnancy in combination with other immunosuppressants. The following malformations were most frequently reported:&nbsp;</strong></p><p dir="ltr"><strong>&bull; Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal atresia (middle ear);</strong></p><p dir="ltr"><strong>&bull; Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits;</strong></p><p dir="ltr"><strong>&bull; Abnormalities of the eye (e.g. coloboma);</strong></p><p dir="ltr"><strong>&bull; Congenital heart disease such as atrial and ventricular septal defects;</strong></p><p dir="ltr"><strong>&bull; Malformations of the fingers (e.g. polydactyly, syndactyly);</strong></p><p dir="ltr"><strong>&bull; Tracheo-oesophageal malformations (e.g. oesophageal atresia);&nbsp;</strong></p><p dir="ltr"><strong>&bull; Nervous system malformations such as spina bifida;&nbsp;</strong></p><p dir="ltr"><strong>&bull; Renal abnormalities.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In addition, there have been isolated reports of the following malformations:</strong></p><p dir="ltr"><strong>&bull; Microphthalmia;</strong></p><p dir="ltr"><strong>&bull; Congenital choroid plexus cyst;</strong></p><p dir="ltr"><strong>&bull; Septum pellucidum agenesis;</strong></p><p dir="ltr"><strong>&bull; Olfactory nerve agenesis.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Studies in animals have shown reproductive toxicity (see section 5.3).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, CellCept is contraindicated in nursing mothers (see section 4.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Men</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Limited clinical evidence does not indicate an increased risk of malformations or miscarriage following paternal exposure to mycophenolate mofetil.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>MPA is a powerful teratogen. It is not known if MPA is present in semen. Calculations based on animal data show that the maximum amount of MPA that could potentially be transferred to woman is so low that it would be unlikely to have an effect. Mycophenolate has been shown to be genotoxic in animal studies at concentrations exceeding the human therapeutic exposures only by small margins such that the risk of genotoxic effects on sperm cells cannot completely be excluded.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Therefore, the following precautionary measures are recommended: sexually active male patients or their female partners are recommended to use reliable contraception during treatment of the male patient and for at least 90 days after cessation of mycophenolate mofetil. Male patients of reproductive potential should be made aware of and discuss with a qualified healthcare professional the potential risks of fathering a child.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>CellCept has a moderate influence on the ability to drive and use machines.&nbsp;</strong></p><p dir="ltr"><strong>CellCept may cause somnolence, confusion, dizziness, tremor or hypotension, and therefore patients are advised to use caution when driving or using machines.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of safety profile</strong></p><p dir="ltr"><strong>An estimated total of 1557 patients received CellCept during five clinical trials in the prevention of acute organ rejection. Of these, 991 were included in the three renal studies, 277 were included in one hepatic study, and 289 were included in one cardiac study. Azathioprine was the comparator used in the hepatic and cardiac studies and in two of the renal studies whilst the other renal study was placebo-controlled. Patients in all study arms also received cyclosporine and corticosteroids. The types of adverse reactions reported during post-marketing with CellCept are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Diarrhoea, leukopenia, sepsis and vomiting were among the most common and/or serious adverse drug reactions associated with the administration of CellCept in combination with ciclosporin and corticosteroids. There is evidence of a higher frequency of certain types of infections (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tabulated list of adverse reactions</strong></p><p dir="ltr"><strong>The adverse drug reactions (ADRs) from clinical trials and post-marketing experience are listed in Table 1, by MedDRA system organ class (SOC) along with their frequencies. The corresponding frequency category for each adverse drug reaction is based on the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Due to the large differences observed in the frequency of certain ADRs across the different transplant indications, the frequency is presented separately for renal, hepatic and cardiac transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 1 Summary of adverse drug reactions occurring in patients treated with CellCept&nbsp;</strong></p><p dir="ltr"><strong>reported from clinical trials and post-marketing experience</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Adverse drug reaction</strong></p>&nbsp;<p dir="ltr"><strong>(MedDRA)</strong></p>&nbsp;<p dir="ltr"><strong>System Organ Class</strong></p></td><td><p dir="ltr"><strong>Renal transplant<br />n = 991</strong></p></td><td><p dir="ltr"><strong>Hepatic transplant<br />n = 277</strong></p></td><td><p dir="ltr"><strong>Cardiac transplant<br />n = 289</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Frequency</strong></p></td><td><p dir="ltr"><strong>Frequency</strong></p></td><td><p dir="ltr"><strong>Frequency</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Infections and infestations&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Bacterial infections</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Fungal infections</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Protozoal infections</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Viral infections</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Benign neoplasm of skin&nbsp;</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Lymphoma</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Lymphoproliferative disorder</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Neoplasm</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Skin cancer</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anemia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Aplasia pure red cell</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Bone marrow failure</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ecchymosis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Leukocytosis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Leukopenia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pancytopenia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pseudolymphoma</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Thrombocytopenia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Metabolism and nutrition disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Acidosis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypercholesterolemia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hyperglycemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hyperkalemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hyperlipidemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypocalcemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypokalemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypomagnesemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypophosphatemia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hyperuricaemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gout</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Weight decreased</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Psychiatric disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Confusional state</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Depression</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Insomnia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Agitation</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anxiety</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Thinking abnormal</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Nervous system disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dizziness</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Headache</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypertonia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Paresthesia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Somnolence</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Tremor</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Convulsion</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dysgeusia</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Cardiac disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Tachycardia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Vascular disorders&nbsp;&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypertension</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypotension</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Lymphocele</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Venous thrombosis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vasodilatation</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Respiratory, thoracic and mediastinal disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Bronchiectasis</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cough</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dyspnea</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Interstitial lung disease</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Very Rare</strong></p></td><td><p dir="ltr"><strong>Very Rare</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pleural effusion</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pulmonary fibrosis</strong></p></td><td><p dir="ltr"><strong>Very Rare</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal distension</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal pain</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Colitis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Constipation</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased appetite</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Diarrhea</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dyspepsia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Esophagitis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Eructation</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Flatulence&nbsp;</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gastritis&nbsp;</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gastrointestinal hemorrhage</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gastrointestinal ulcer</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Gingival hyperplasia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ileus</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Mouth ulceration</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nausea</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pancreatitis</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Stomatitis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vomiting</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Immune system disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypersenstivity</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypogammaglobulinaemia</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Very Rare</strong></p></td><td><p dir="ltr"><strong>Very Rare</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Hepatobiliary disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Blood alkaline phosphatase increased&nbsp;</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Blood lactate dehydrogenase increased&nbsp;</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hepatic enzyme increased&nbsp;</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hepatitis</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hyperbilirubinaemia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Jaundice</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Skin and subcutaneous tissue disorders&nbsp;&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Acne</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Alopecia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Rash</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Skin hypertrophy</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Musculoskeletal and connective tissue disorders&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Arthralgia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Muscular weakness</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p dir="ltr"><strong>Blood creatinine increased</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Blood urea increased</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hematuria</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Renal impairment</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td colspan="4"><p dir="ltr"><strong>General disorders and administration site conditions&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Asthenia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Chills</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Edema</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hernia</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Malaise</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pain</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pyrexia</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td><td><p dir="ltr"><strong>Very Common</strong></p></td></tr></tbody></table><p dir="ltr"><strong>Note: 991 (2&nbsp;g / 3&nbsp;g CellCept daily), 289 (3&nbsp;g CellCept daily) and 277 (2&nbsp;g IV / 3&nbsp;g oral CellCept daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Description of selected adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Malignancies</strong></p><p dir="ltr"><strong>Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p dir="ltr"><strong>All patients treated with immunosuppressants are at increased risk of bacterial, viral and fungal infections (some of which may lead to a fatal outcome), including those caused by opportunistic agents and latent viral reactivation. The risk increases with total immunosuppressive load (see section 4.4). The most serious infections were sepsis, peritonitis, meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. The most common opportunistic infections in patients receiving CellCept (2&nbsp;g or 3&nbsp;g daily) with other immunosuppressants in controlled clinical trials in renal, cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. The proportion of patients with CMV viraemia/syndrome was 13.5%. Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Blood and lymphatic disorders&nbsp;</strong></p><p dir="ltr"><strong>Cytopenias, including leukopenia, anemia, thrombocytopenia and pancytopenia, are known risks associated with mycophenolate mofetil and may lead or contribute to the occurrence of infections and hemorrhages (see section 4.4). Agranulocytosis and neutropenia have been reported; therefore, regular monitoring of patients taking CellCept is advised (see section 4.4). There have been reports of aplastic anaemia and bone marrow failure in patients treated with CellCept, some of which have been fatal.</strong></p><p dir="ltr"><strong>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with CellCept (see section 4.4).</strong></p><p dir="ltr"><strong>Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with CellCept. These changes are not associated with impaired neutrophil function. These changes may suggest a &lsquo;left shift&rsquo; in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive CellCept.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Gastrointestinal disorders</strong></p><p dir="ltr"><strong>The most serious gastrointestinal disorders were ulceration and hemorrhage which are known risks associated with mycophenolate mofetil. Mouth, esophageal, gastric, duodenal, and intestinal ulcers often complicated by hemorrhage, as well as hematemesis, melena, and hemorrhagic forms of gastritis and colitis were commonly reported during the pivotal clinical trials. The most common gastrointestinal disorders, however, were diarrhea, nausea and vomiting. Endoscopic investigation of patients with CellCept-related diarrhea have revealed isolated cases of intestinal villous atrophy (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hypersensitivity</strong></p><p dir="ltr"><strong>Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy, puerperium and perinatal conditions</strong></p><p dir="ltr"><strong>Cases of spontaneous abortion have been reported in patients exposed to mycophenolate mofetil, mainly in the first trimester, see section 4.6.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Congenital disorders</strong></p><p dir="ltr"><strong>Congenital malformations have been observed post-marketing in children of patients exposed to CellCept in combination with other immunosuppressants, see section 4.6.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p dir="ltr"><strong>There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with CellCept in combination with other immunosuppressants, some of which have been fatal. There have also been reports of bronchiectasis in children and adults.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immune system disorders</strong></p><p dir="ltr"><strong>Hypogammaglobulinaemia has been reported in patients receiving CellCept in combination with other immunosuppressants.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>General disorders and administration site conditions</strong></p><p dir="ltr"><strong>Edema, including peripheral, face and scrotal edema, was reported very commonly during the pivotal trials. Musculoskeletal pain such as myalgia, and neck and back pain were also very commonly reported.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population&nbsp;</strong></p><p dir="ltr"><strong>The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600&nbsp;mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1&nbsp;g CellCept twice daily. However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leukopenia, anaemia and infection.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly&nbsp;</strong></p><p dir="ltr"><strong>Elderly patients (&ge;&nbsp;65 years) may generally be at increased risk of adverse reactions due to immunosuppression. Elderly patients receiving CellCept as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Saudi Arabia:</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong><img width="550" height="135" src="https://docs.google.com/drawings/u/0/d/sGFm4ecJXieTbcQ6g2QGAJA/image?w=550&amp;h=135&amp;rev=1&amp;ac=1&amp;parent=1HXDyou_6SPKJQf0_jnoTc1-G-hFroVkg" /></strong></p><p>&nbsp;</p><ul><li dir="ltr"><p dir="ltr"><strong>Other GCC States:</strong></p></li></ul><p dir="ltr"><strong><img width="550" height="37" src="https://docs.google.com/drawings/u/0/d/szWwzFXQailPnXvbi5ce9wg/image?w=550&amp;h=37&amp;rev=1&amp;ac=1&amp;parent=1HXDyou_6SPKJQf0_jnoTc1-G-hFroVkg" /></strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience. In many of these cases, no adverse events were reported. In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the medicinal product.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with CellCept should be interrupted or the dose reduced (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Haemodialysis would not be expected to remove clinically significant amounts of MPA or MPAG. Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic recirculation of the drug (see section 5.2).</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: immunosuppressive agents ATC code L04AA06</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mechanism of action</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Absorption</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Following oral administration, mycophenolate mofetil undergoes rapid and extensive absorption and complete presystemic metabolism to the active metabolite, MPA. As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of CellCept is correlated with MPA concentration. The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5&nbsp;g BID to renal transplant patients. However, MPA Cmax was decreased by 40% in the presence of food. Mycophenolate mofetil is not measurable systemically in plasma following oral administration.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Distribution</strong></p><p>&nbsp;</p><p dir="ltr"><strong>As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 &ndash; 12 hours post-dose. A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4&nbsp;g TID), indicating that there is a significant amount of enterohepatic recirculation.&nbsp;</strong></p><p dir="ltr"><strong>MPA at clinically relevant concentrations is 97% bound to plasma albumin.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Biotransformation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>MPA is metabolised principally by glucuronyl transferase (isoform UGT1A9) to form the inactive phenolic glucuronide of MPA (MPAG). In vivo, MPAG is converted back to free MPA via enterohepatic recirculation. A minor acylglucuronide (AcMPAG) is also formed. AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF&rsquo;s side effects (diarrhoea, leukopenia).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A negligible amount of substance is excreted as MPA (&lt;&nbsp;1% of the dose) in the urine. Oral administration of radiolabelled mycophenolate mofetil results in complete recovery of the administered dose with 93% of the administered dose recovered in the urine and 6% recovered in the faeces. Most (about 87%) of the administered dose is excreted in the urine as MPAG.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>At clinically encountered concentrations, MPA and MPAG are not removed by haemodialysis. However, at high MPAG plasma concentrations (&gt;&nbsp;100&nbsp;&micro;g/ml), small amounts of MPAG are removed. By interfering with enterohepatic recirculation of the drug, bile acid sequestrants such as cholestyramine, reduce MPA AUC (see section 4.9).</strong></p><p dir="ltr"><strong>MPA&rsquo;s disposition depends on several transporters. Organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA&rsquo;s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides&rsquo; biliary excretion. Multidrug resistance protein 1 (MDR1) is also able to transport MPA, but its contribution seems to be confined to the absorption process. In the kidney, MPA and its metabolites potently interact with renal organic anion transporters.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the early post-transplant period (&lt;&nbsp;40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 &ndash; 6 months post-transplant).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special populations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p dir="ltr"><strong>In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate &lt;&nbsp;25&nbsp;ml/min/1.73&nbsp;m2) were 28 &ndash; 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. The mean single dose MPAG AUC was 3 &ndash; 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. Multiple dosing of mycophenolate mofetil in patients with severe chronic renal impairment has not been studied. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Delayed renal graft function</strong></p><p dir="ltr"><strong>In patients with delayed renal graft function post-transplant, mean MPA AUC0-12h was comparable to that seen in post-transplant patients without delayed graft function. Mean plasma MPAG AUC 0-12h was 2 &ndash; 3-fold higher than in post-transplant patients without delayed graft function. There may be a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. Dose adjustment of CellCept does not appear to be necessary.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hepatic impairment</strong></p><p dir="ltr"><strong>In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. Effects of hepatic disease on this process probably depend on the particular disease. However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population&nbsp;</strong></p><p dir="ltr"><strong>Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18 years) given 600&nbsp;mg/m2 mycophenolate mofetil orally twice daily. This dose achieved MPA AUC values similar to those seen in adult renal transplant patients receiving CellCept at a dose of 1&nbsp;g BID in the early and late post-transplant period. MPA AUC values across age groups were similar in the early and late post-transplant period.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>The pharmacokinetics of mycophenolate mofetil and its metabolites have not been found to be altered in the elderly patients (&ge;&nbsp;65 years) when compared to younger transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients taking oral contraceptives</strong></p><p dir="ltr"><strong>A study of the co-administration of CellCept (1&nbsp;g BID) and combined oral contraceptives containing ethinylestradiol (0.02&nbsp;mg to 0.04&nbsp;mg) and levonorgestrel (0.05&nbsp;mg to 0.15&nbsp;mg), desogestrel (0.15&nbsp;mg) or gestodene (0.05&nbsp;mg to 0.10&nbsp;mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of CellCept on the ovulation suppressing action of the oral contraceptives. Serum levels of LH, FSH and progesterone were not significantly affected. The pharmacokinetics of oral contraceptives were unaffected by co-administration of CellCept (see also section 4.5).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>In experimental models, mycophenolate mofetil was not tumourigenic. The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 &ndash; 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2&nbsp;g/day and 1.3 &ndash; 2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3&nbsp;g/day.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Two genotoxicity assays (in vitro mouse lymphoma assay and in vivo mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations. These effects can be related to the pharmacodynamic mode of action, i.e. inhibition of nucleotide synthesis in sensitive cells. Other in vitro tests for detection of gene mutation did not demonstrate genotoxic activity.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20&nbsp;mg/kg/day. The systemic exposure at this dose represents 2 &ndash; 3 times the clinical exposure at the recommended clinical dose of 2&nbsp;g/day in renal transplant patients and 1.3 &ndash; 2 times the clinical exposure at the recommended clinical dose of 3&nbsp;g/day in cardiac transplant patients. In a female fertility and reproduction study conducted in rats, oral doses of 4.5&nbsp;mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2&nbsp;g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3&nbsp;g/day for cardiac transplant patients. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at&nbsp;</strong></p><p dir="ltr"><strong>6&nbsp;mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90&nbsp;mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2&nbsp;g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3&nbsp;g/day for cardiac transplant patients (see section 4.6).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey. These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2&nbsp;g/day for renal transplant recipients. Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose. Gastrointestinal and renal effects consistent with dehydration were also observed in the monkey at the highest dose (systemic exposure levels equivalent to or greater than clinical exposure). The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials, which now provide safety data of more relevance to the patient population (see section 4.8).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>CellCept tablets</strong></p><p dir="ltr"><strong>microcrystalline cellulose</strong></p><p dir="ltr"><strong>polyvidone (K-90)</strong></p><p dir="ltr"><strong>croscarmellose sodium&nbsp;</strong></p><p dir="ltr"><strong>magnesium stearate</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tablet coating</strong></p><p dir="ltr"><strong>hydroxypropyl methylcellulose</strong></p><p dir="ltr"><strong>hydroxypropyl cellulose</strong></p><p dir="ltr"><strong>titanium dioxide (E171)</strong></p><p dir="ltr"><strong>polyethylene glycol 400</strong></p><p dir="ltr"><strong>indigo carmine aluminium lake (E132)</strong></p><p dir="ltr"><strong>red iron oxide (E172)</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Not applicable.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Do not store above 30&nbsp;&deg;C. Keep the blister in the outer carton in order to protect from light.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>PVC/aluminium foil blister strips</strong></p><p dir="ltr"><strong>CellCept 500&nbsp;mg film-coated tablets: 1 carton contains 50 tablets (in blister packs of 10)</strong></p><p dir="ltr"><strong>multipacks containing 150 (3 packs of 50) tablets</strong></p><p dir="ltr"><strong>Not all pack sizes may be marketed.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd, 
Grenzacherstrasse 124
CH-4070 Basel
Switzerland.

8.	MARKETING AUTHORISATION NUMBER(S) 

281-24-16


9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 05 March 2000
Date of latest renewal: 25 July 2016


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 February 2020

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>